P.R. Herzig & Co. Inc. continued to hold its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, Holdings Channel reports. The fund owned 37,650 shares of the pharmaceutical company’s stock at the end of the second quarter. GlaxoSmithKline PLC accounts for about 3.1% of P.R. Herzig & Co. Inc.’s portfolio, making the stock its 14th largest position. P.R. Herzig & Co. Inc.’s holdings in GlaxoSmithKline PLC were worth $1,623,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in GSK. Lincluden Management Ltd. increased its position in GlaxoSmithKline PLC by 1.7% in the first quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock valued at $5,095,000 after buying an additional 1,990 shares during the last quarter. Anchor Capital Advisors LLC increased its position in GlaxoSmithKline PLC by 9.6% in the first quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock valued at $25,858,000 after buying an additional 53,894 shares during the last quarter. Roundview Capital LLC increased its position in GlaxoSmithKline PLC by 157.4% in the first quarter. Roundview Capital LLC now owns 24,529 shares of the pharmaceutical company’s stock valued at $1,034,000 after buying an additional 15,000 shares during the last quarter. Dodge & Cox purchased a new position in GlaxoSmithKline PLC during the fourth quarter valued at $1,416,000. Finally, Wesbanco Bank Inc. increased its position in GlaxoSmithKline PLC by 2.8% in the first quarter. Wesbanco Bank Inc. now owns 12,765 shares of the pharmaceutical company’s stock valued at $538,000 after buying an additional 350 shares during the last quarter. 8.96% of the stock is owned by hedge funds and other institutional investors.

Shares of GlaxoSmithKline PLC (GSK) traded up 0.719% during trading on Wednesday, reaching $42.735. The company’s stock had a trading volume of 424,285 shares. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $45.58. The company has a 50 day moving average of $43.35 and a 200-day moving average of $41.69. The stock has a market cap of $104.40 billion, a price-to-earnings ratio of 48.562 and a beta of 1.04.

GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings data on Wednesday, April 26th. The pharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.62. The business had revenue of $9.23 billion during the quarter, compared to analyst estimates of $9.09 billion. GlaxoSmithKline PLC had a return on equity of 113.31% and a net margin of 5.48%. Analysts forecast that GlaxoSmithKline PLC will post $2.86 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, July 13th. Stockholders of record on Friday, May 12th were paid a $0.483 dividend. This represents a $1.93 annualized dividend and a dividend yield of 4.55%. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date was Wednesday, May 10th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 233.74%.

COPYRIGHT VIOLATION NOTICE: “P.R. Herzig & Co. Inc. Has $1,623,000 Stake in GlaxoSmithKline PLC (NYSE:GSK)” was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/p-r-herzig-co-inc-has-1623000-stake-in-glaxosmithkline-plc-nysegsk/1452690.html.

Several research analysts have recently weighed in on GSK shares. BNP Paribas cut their price target on GlaxoSmithKline PLC to $37.00 in a research note on Thursday, April 6th. TheStreet upgraded GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research note on Friday, May 19th. Berenberg Bank upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research note on Friday, May 26th. Zacks Investment Research upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Tuesday. Finally, ValuEngine downgraded GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $46.00.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.